0.05
—
Close of 9 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Telo Genomics
Its shares trade on TSX Venture under the ticker TELO.V. It has been listed since 15 February 2012.
Telo Genomics Corp. is a biotechnology company, which engages in the development and commercialization of technological products designed to personalize treatment plans for patients who have specific conditions. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-02-15. The firm is focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions. The Company, through its wholly owned subsidiary, Telo Genomics Holdings Corp., is developing diagnostic and prognostic products for diseases that display genomic instability. Its lead product, TeloView SMM, is a high-complexity molecular assay available for clinical use to provide information to physicians treating patients with Smoldering Multiple Myeloma. Through proprietary telomere-based analysis, TeloView SMM selects high-risk SMM patients who are likely to benefit from earlier treatment intervention while identifying the larger subset of low-risk SMM patients who have a more stable form of the disease and do not require immediate treatment. The TeloView SMM assay has a potential total addressable market of over 500,000 tests per year.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Feb 2012
- Website
- telodx.com ↗
Leadership
Pay as last reported
- Mr. Guido BaechlerExecutive Chairman of the Board, since 2019C$81,667
- Dr. Sabine MaiInterim Chief Executive Officer, Director, Chair of the Clinical and Scientific Advisory Board, since 2016C$30,000
- Mr. Christopher RossChief Financial OfficerC$60,000
- Mr. John FarlingerDirector
- Dr. Ron McglennenIndependent DirectorC$40,833
- Mr. John MeekisonIndependent DirectorC$18,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Headquartered in Toronto, Ontario, Canada.
- Focuses on developing predictive technological products for personalized treatment plans.
- Owns a lead product, TeloView SMM, for Smoldering Multiple Myeloma diagnosis.
Weaknesses
- Operates in a highly competitive biotechnology sector.
- Relies on a single lead product, TeloView SMM, for commercialization.
- Limited market information provided for the TeloView SMM assay.
Opportunities
- Potential to expand the use of TeloView SMM to other diseases with genomic instability.
- Growing demand for personalized medicine in healthcare.
- Opportunity to develop additional diagnostic and prognostic products.
Threats
- Dependence on a single product may pose commercial risks.
- Regulatory challenges in the biotechnology and healthcare sectors.
- Competition from other biotechnology companies in the same market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.